ArticleAntimicrobial agents and chemotherapy2012
Dynamic interaction between fluconazole and amphotericin B against Cryptococcus gattii.
Article in Antimicrobial agents and chemotherapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 63 citations in OpenAlex.
- Synergic Effect of Fluconazole and Quinoline Derivatives Combination AgainstMicroorganisms · 2026Article
- Therapeutic potential and synergistic effects of antifungal and off target drugs against clinical isolates of Cryptococcus laurentii.Scientific reports · 2026Article
- New Chlorinated Meroterpenoids with Antifungal Activity from the Deep-Sea-Derived FungusMarine drugs · 2026Article
- Thiazole Derivatives as Promising Candidates for Cryptococcosis Therapy.ACS infectious diseases · 2025Article
- Influence of the agrochemical benomyl on Cryptococcus gattii-plant interaction in vitro and in vivo.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- Novel combinatorial approach: Harnessing HIV protease inhibitors to enhance amphotericin B's antifungal efficacy in cryptococcosis.PloS one · 2024Article
- Article
- Selection of Ethanol Tolerant Strains ofbioRxiv : the preprint server for biology · 2023Article
- In Silico and In Vitro Analysis of Sulforaphane Anti-Antibiotics (Basel, Switzerland) · 2022Article
- Comparison of amphotericin B deoxycholate in combination with either flucytosine or fluconazole, and voriconazole plus flucytosine for the treatment of HIV-associated cryptococcal meningitis: a prospective multicenter study in China.BMC infectious diseases · 2022Article
- Ethyl Acetate Fraction ofAntibiotics (Basel, Switzerland) · 2022Article
- Article
- Activity and Mechanism of Action of Antifungal Peptides from Microorganisms: A Review.Molecules (Basel, Switzerland) · 2021Review
- Actin cytoskeletal inhibitor 19,20-epoxycytochalasin Q sensitizes yeast cells lacking ERG6 through actin-targeting and secondarily through disruption of lipid homeostasis.Scientific reports · 2021Article
- Inhibitory effect of magnetic iron-oxide nanoparticles on the pattern of expression of lanosterol 14IET nanobiotechnology · 2020Article
- A Study of the Disruptive Effect of the Acetate Fraction ofFrontiers in microbiology · 2020Article
- Synergistic antifungal interactions of amphotericin B with 4-(5-methyl-1,3,4-thiadiazole-2-yl) benzene-1,3-diol.Scientific reports · 2019Article
- Evaluation ofFrontiers in microbiology · 2019Article
- Short-Course Rather Than Low-Dose Amphotericin B May Exert Potential Influence on Mortality in Cryptococcal Meningitis Patients Treated With Amphotericin B Plus Flucytosine Alone or in Combination With Fluconazole.Frontiers in microbiology · 2019Article
- Transcriptional Heterogeneity ofmSphere · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cryptococcus gattii is the main pathogen of cryptococcosis in healthy patients and is treated mainly with fluconazole and amphotericin B. The combination of these drugs has been questioned because the mechanisms of action could lead to a theoretical antagonistic interaction. We evaluated distinct parameters involved in the in vitro combination of fluconazole and amphotericin B against Cryptococcus gattii. Fourteen strains of C. gattii were used for the determination of MIC, fractional inhibitory concentration, time-kill curve, and postantifungal effect (PAFE). Ergosterol quantification was performed to evaluate the influence of ergosterol content on the interaction between these antifungals. Interaction between the drugs varied from synergistic to antagonistic depending on the strain and concentration tested. Increasing fluconazole levels were correlated with an antagonistic interaction. A total of 48 h was necessary for reducing the fungal viability in the presence of fluconazole, while 12 h were required for amphotericin B. When these antifungals were tested in combination, fluconazole impaired the amphotericin B activity. The ergosterol content decreased with the increase of fluconazole levels and it was correlated with the lower activity of amphotericin B. The PAFE found varied from 1 to 4 h for fluconazole and from 1 to 3 h for amphotericin B. The interaction of fluconazole and amphotericin B was concentration-dependent and special attention should be directed when these drugs are used in combination against C. gattii.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.